Aktie CESSA CESSATECH A/S
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Cessatech A/S

Aktien

CESSA

DK0061411964

CESSA

Schlusskurs NORDIC GROWTH MARKET
Andere Börsenplätze
 00:00:00 30.04.2024 		% 5 Tage % 1. Jan.
6,36 DKK +0,32 % Intraday Chart für Cessatech A/S +2,58 % -12,40 %
29.02. Cessatech A/S meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI
2023 Cessatech A/S meldet Ergebnis für das dritte Quartal und die neun Monate bis zum 30. September 2023 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
A short business update
Minutes from the Annual General Meeting in Cessatech A/S
Annual General Meeting - 27 March 2024
Cessatech A/S publishes Annual Report for the fiscal year 2023
Cessatech A/S Reports Earnings Results for the Full Year Ended December 31, 2023
CESSATECH ANNOUNCES RESULT OF WARRANT EXERCISE FOR WARRANTS OF SERIES TO2
LAST DAY OF TRADING IN WARRANTS OF SERIES TO2 IN CESSATECH IS TOMORROW, JANUARY 24, 2024
CESSATECH ANNOUNCES THAT MANAGEMENT AND BOARD HAVE EXERCISED ALL THEIR WARRANTS OF SERIES TO2
CESSATECH ANNOUNCES THE START OF THE EXERCISE PERIOD FOR WARRANTS OF SERIES TO2
CESSATECH ANNOUNCES TO2 WARRANT EXERCISE PRICE AND START OF EXERCISE PERIOD
Q&A session related topline data Study 0205
Cessatech: Cessatech announces positive topline data from study 0205 with its lead candidate CT001 for the treatment of pain in children supporting further advancement of CT001
Third Quarter Report Q3-2023
Cessatech A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Cessatech announces that the Paediatric Committee has agreed to a 50% reduction of the required number of patients in the final study of its nasal spray for the treatment of acute pain in children
Cessatech A/S Announces the Paediatric Committee Agrees to Reduce the Number of Required Children in the Final Clinical Study with CT001 from 300 to 150 Children
Cessatech announces last participant dosed in pivotal trial 0205 with lead candidate CT001
Cessatech Announces Last Participant Dosed in Pivotal Trial 0205 with Lead Candidate CT001
Cessatech Wins EU Nod for Clinical Studies of Nasal Sedation Spray in Children; Shares Soar 21%
Cessatech announces agreement with the European Medicines Agency on a Paediatric Investigational Plan for its second asset CT002 for medical procedural sedation in children
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. CESSA Aktie
  4. Nachrichten Cessatech A/S
  5. Andere Sprachen